J&J/Cordis' ExoSeal
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson subsidiary Cordis will enter the vascular closure device market in June with the European debut of its ExoSeal system. The bioabsorbable polyglycolic acid plug system, which is designed to close femoral artery puncture sites, received CE-mark approval in May. "An advantage compared to other devices is the procedural sheath does not need to be changed, which helps promote patient comfort," Cordis claims. Competing systems include Abbott's StarClose and St. Jude Medical's AngioSeal